相关实验视频

Updated: Jul 16, 2025

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

立体体辐射疗法用于小进步性和小重复性非小细胞肺癌

Maryam Ebadi¹, Colton Ladbury², Jason Liu²

¹Department of Radiation Oncology, University of Washington, Seattle, WA.

Clinical lung cancer

|September 15, 2023

概括

立体体辐射疗法 (SBRT) 是非小细胞肺癌 (NSCLC) 的安全选择,进展有限. 用SBRT治疗的转移部位较少的患者经历了更好的生存结果.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
医学物理医学物理

背景情况:

刻板体辐射疗法 (SBRT) 在寡进性非小细胞肺癌 (NSCLC) 中的作用仍在争论中.
评估SBRT在维持持久反应和避免全身治疗更改方面的有效性至关重要.

研究的目的:

评估SBRT在治疗寡进性或寡重复性NSCLC中的有效性.
确定SBRT是否可以提供持久的反应,从而可能延迟或消除对新系统治疗的需求.

主要方法:

对168名接受SBRT治疗的NSCLC患者进行了回顾性分析.
系统治疗期间/之后的5个病变的进展;系统治疗结束后的进展.
关键结局包括无进展生存率 (PFS),总生存率 (OS) 和到下一次治疗或死亡的时间 (TNT-D).

主要成果:

两年的OS和PFS分别为56%和14%. 中位数TNT-D是9个月.
没有观察到4级或5级毒性,这表明SBRT的安全性.
与0至2个转移性进展部位的患者相比,与3至5个部位的患者相比,转移性进展部位的患者的生存状况明显更好,TNT-D时间更长.

结论:

SBRT是对寡进性和寡复性NSCLC的安全有效治疗方法.
较少转移部位 (0-2) 的患者的SBRT与有利的生存结果 (OS,TNT-D) 有关.
对于具有有限转移性进展的选择性NSCLC患者来说,SBRT是一种可行的治疗策略.

关键词:

转移转移转移转移在NSCLCLC中,我们可以看到.寡头进步的发展的复发情况.在SBRT和SBRT之间.

更多相关视频

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...